Seattle Genetics is one of the finest medication service firms in America, and they are progressing with a plan to offer a new brand that will help everyone diagnosed with cancer. This article explains how their most recent earnings report shows the ADCETRIS name is becoming the hallmark Seattle Genetics needs, and Clay Siegall is offering proper leadership for his newest venture.
#1: ADCETRIS Is Showing Positive Gains
ADCETRIS is a tumor-fighting drug that was created at Seattle Genetics under the guidance of Clay and his staff. The company is reporting record sales over $60 million, and ADCETRIS is progressing quite well in trials with new patients. Every patient has a higher likelihood of recovering from a tumor or growth with the ADCETRIS program, and Seattle Genetics is pleased with their most recent gains.
#2: Who Does Seattle Genetics Work With?
Seattle Genetics works with quite a few partners while creating their newest drugs. Clay has signed deals with some of the largest drug companies in the world for further development, and the Seattle Genetics staff is creating new products consistently for their clients. The combination of research success and sales growth at Seattle Genetics has helped quite a few ill patients.
#3: AETHERA Trials
There is a new lymphoma product from Seattle Genetics called AETHERA, and the results of the trials inform how ADCETRIS will progress in the future. Clay is a brilliant businessman who has made wise decisions for his firm, and he has multiple trials going that will mean millions of dollars in sales due to the success of the drugs.
Seattle Genetics has become one of the finest providers of cancer and oncology services in America, and their most recent earnings reports show massive success. It is quite easy to see how their research is producing life-saving results for cancer patients across America.